Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2021 | How can we develop better DMTs in Huntington’s disease?

Anne Rosser • 23 Sep 2021
MDS 2021
Huntington’s Disease Movement Disorders

Anne Rosser, PhD, FRCP, Cardiff University, Cardiff, UK, underlines the importance of better understanding the fundamental mechanisms of Huntington’s disease pathology to improve current treatment approaches and develop new effective disease modifying therapies (DMTs). It is particularly important to determine how the mutant huntingtin protein causes disease, as well as how the normal protein functions. This interview took place during the 2021 International Congress of Parkinson’s Disease and Movement Disorders.

More from Anne Rosser

A multidisciplinary approach to providing care in Huntington’s disease
3:28
A multidisciplinary approach to providing care in Huntington’s disease
Anne Rosser • 23 Sep 2021
Update: novel disease-modifying treatments in development for Huntington’s disease
2:20
Update: novel disease-modifying treatments in development for Huntington’s disease
Anne Rosser • 23 Sep 2021
Phase I trial of fetal striatal cell transplantation in Huntington’s disease
2:58
Phase I trial of fetal striatal cell transplantation in Huntington’s disease
Anne Rosser • 23 Sep 2021
Therapies in the pipeline for Huntington's disease
1:54
Therapies in the pipeline for Huntington's disease
Anne Rosser • 18 Jun 2021

Related Videos

Emerging therapies for neurologic Wilson's disease
2:42
Emerging therapies for neurologic Wilson's disease
Aurelia Poujois • 29 Jun 2026
Findings from the Phase III FoCus trial: tiomolibdate choline for neurologic Wilson's disease
3:18
Findings from the Phase III FoCus trial: tiomolibdate choline for neurologic Wilson's disease
Aurelia Poujois • 29 Jun 2026
Current treatment and unmet needs in neurologic Wilson's disease
3:15
Current treatment and unmet needs in neurologic Wilson's disease
Aurelia Poujois • 29 Jun 2026
Guidance for clinicians on the real-world use of foslevodopa/foscarbidopa for PD
7:39
Guidance for clinicians on the real-world use of foslevodopa/foscarbidopa for PD
K. Ray Chaudhuri • 30 Jun 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals